

Transformative Potential of Artificial Intelligence in Enhancing Oral and Maxillofacial Cancer Care for a Brighter Tomorrow

MD. ASADUZZAMAN¹, MD. ABDUR RAHMAN², NITISH KRISHNA DAS³,
MAUSUMI IQBAL⁴, A K M SHAFIUL KADIR^{5*}, MD. GOLAM RABBANY¹,
MOHAMMAD ULLAH SHEMANTO⁶, RUKAIYA AKHTER⁶ and JOYE KUNDU⁷

¹Rangpur Community Dental College, Rangpur, Bangladesh.

²Dental Unit, Rangpur Medical College, Rangpur, Bangladesh.

³Dental Unit, Shaheed Suhrawardy Medical College, Dhaka, Bangladesh.

⁴Bangladesh Oral Cancer Society, Dhaka, Bangladesh.

⁵Quest Bangladesh Biomedical Research Center, Dhaka, Bangladesh.

⁶Ahsania Mission Cancer and General Hospital (AMCGH), Dhaka, Bangladesh.

⁷Department of Biomedical Engineering, Military Institute of Science and Technology, Dhaka, Bangladesh.

Abstract

The integration of Artificial Intelligence (AI) has significantly advanced oral and maxillofacial cancer (OMC) care. This paper explores the transformative potential of AI in OMC diagnosis, staging, treatment, and prognosis. AI-driven applications, including computer vision and machine learning, are discussed, emphasizing their impact on early detection, accurate diagnosis, and personalized treatment planning. The paper also explores the role of AI in OMC education, research, and practice, outlining future directions. In OMC staging, AI automates the process by analyzing medical records and imaging data, enhancing accuracy. The paper also discusses AI's role in tailoring treatment plans, optimizing radiation therapy, and facilitating robotic surgery. Furthermore, the integration of ChatGPT in OMC education, research, and practice is explored. The paper outlines future directions, including the integration of multi-omics data and real-time patient monitoring, emphasizing collaboration, clinical trials, and validation as essential steps in realizing AI's potential in routine clinical practice. In conclusion, AI has the potential to transform OMC management by enhancing diagnosis accuracy, staging precision, personalized treatment planning, and prognosis estimation. Addressing ethical concerns and fostering interdisciplinary collaboration are crucial in harnessing AI's capabilities. By embracing AI advancements, OMC care can be significantly improved, leading to better patient outcomes and contributing to the fight against oral and maxillofacial cancer.



Article History

Received: 28 September 2023

Accepted: 13 December 2023

Keywords

AI Applications;
Artificial Intelligence;
ChatGPT;
Diagnosis;
Maxillofacial Cancer;
Oral; Staging;
Treatment; prognosis.

CONTACT A K M Shafiul Kadir ✉ shafiul_kadir@yahoo.com 📍 Quest Bangladesh Biomedical Research Center, Dhaka, Bangladesh.



© 2025 The Author(s). Published by Enviro Research Publishers.

This is an Open Access article licensed under a Creative Commons license: Attribution 4.0 International (CC-BY).

Doi: <https://dx.doi.org/10.12944/EDJ.06.SI01.02>

Introduction

Within the complex landscape of head and neck cancers, Oral and Maxillofacial Cancer (OMC) stands out as a distinct entity, undergoing a transformative shift in management practices through the integration of state-of-the-art Artificial Intelligence (AI) technologies. Oral and Maxillofacial Cancer (OMC) is a comprehensive term encompassing various cancers occurring in areas such as the oral cavity, pharynx, larynx, paranasal sinuses, and nearby structures. These cancers, whether malignant or benign, significantly impact public health. In 2023, an estimated 66,920 people (49,190 men and 17,730 women) will be diagnosed with oral and maxillofacial cancer. Worldwide, an estimated 562,328 people were diagnosed with oral and maxillofacial cancer in 2020. It is estimated that 15,400 deaths (11,210 men and 4,190 women) from oral and maxillofacial cancer will occur in the United States in 2023.¹ One of the major challenges in managing OMC is the late-stage diagnosis, which often leads to poor prognosis and lower survival rates. The delay in detection increases the complexity and severity of the treatment, resulting in higher morbidity and mortality rates among patients.²

As per the World Health Organization, OMC is responsible for approximately 550,000 new cases and 380,000 deaths worldwide every year. Late diagnosis worsens the disease's severity, resulting in a five-year survival rate of around 40-50%, significantly lower than cancers diagnosed at earlier stages.³ Oral and maxillofacial cancer (OMC) poses significant challenges despite advancements in medical technology. Early detection, accurate diagnosis, and personalized treatment planning are critical for improving patient outcomes. This paper explores the transformative potential of Artificial Intelligence (AI) in addressing these challenges. AI applications, including computer vision and machine learning, offer unique opportunities for enhancing various aspects of OMC diagnosis, treatment, and prognosis. AI has an impressive ability to analyze complex datasets and identify subtle patterns, making it a promising tool for early and accurate diagnosis of OMC.⁴

By utilizing AI-driven applications like machine learning and deep learning, we hope to fill the gap in early screening and diagnosis, which is crucial for improving patient outcomes and increasing

survival rates in OMC cases. The potential of AI to transform OMC care is a beacon of hope for a future where timely and accurate diagnoses lead to more effective treatments and improved prognoses.⁵ Recent advancements in genetic research have revealed potential markers for malignant disorders in the oral and maxillofacial region, providing a new dimension for early detection and intervention strategies in OMC management. This genetic revelation underscores the importance of integrating AI with genetic data to enhance our understanding of disease progression and to develop personalized treatment plans for patients.⁶

This paper aims to highlight the potential of AI in revolutionizing OMC management and emphasizes the need to adopt this transformative technology for improving patient care and outcomes. By leveraging AI-driven applications like machine learning and deep learning, we aim to address the research gap in improving early screening and diagnosis for OMC. This technology has the potential to identify high-risk individuals, enhance staging accuracy, personalize treatment plans, optimize therapeutic approaches, and ultimately lead to better patient outcomes. Understanding that patients diagnosed at advanced stages often have poor prognoses while those diagnosed at earlier stages have better outcomes highlights the importance of emphasizing the role of AI in early screening and diagnosis. This focus is crucial for improving the overall management of Oral and Maxillofacial Cancer.

Methodology

This article is structured as a narrative review aiming to synthesize and analyze existing literature regarding the role of Artificial Intelligence (AI) in Oral and Maxillofacial Cancer (OMC) management. A narrative review is employed to provide a comprehensive overview and critical analysis of the current state of AI applications in OMC, including diagnosis, staging, treatment, and prognosis. The review seeks to present a cohesive narrative, summarize key findings, and discuss the potential transformative impact of AI in OMC care. This paper was developed through a comprehensive review of existing literature on the application of Artificial Intelligence (AI) in the management of Oral and Maxillofacial Cancer (OMC). The literature was sourced from reputable scientific databases,

including PubMed, Scopus, Science Direct, Google Scholar, and Cochrane using Boolean operators. The search for articles was conducted using relevant keywords. The criteria for inclusion in this paper were articles about AI applications in OMC published online, articles in English, and articles with both experimental and observational research. Incomplete and inaccessible articles were excluded. The data retrieval process began with the selection and determination of literature that was relevant to the objectives and met the inclusion criteria. The inclusion of diverse perspectives and studies is aimed at offering a well-rounded understanding of the subject, allowing readers to grasp the scope and potential of AI in the context of oral and maxillofacial cancer.

Oraland Maxillofacial Cancer (OMC) Diagnosis and AI Applications

The importance of early detection and accurate diagnosis in the effective management of Oral and Maxillofacial Cancer (OMC) cannot be overstated, as these factors directly influence patient outcomes and prognosis. The integration of Artificial Intelligence (AI) in healthcare has shown promising advancements across various medical domains, including cancer diagnosis. AI-powered technologies, particularly sophisticated computer vision algorithms, hold immense potential in revolutionizing OMC diagnosis by leveraging advanced image analysis techniques and predictive models based on a diverse range of patient data.⁷

AI-powered Computer Vision for OMC Detection

AI-driven computer vision technologies exhibit a remarkable capability to analyze a diverse array of imaging modalities frequently employed in OMC diagnosis, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. These cutting-edge algorithms play a pivotal role in processing and deciphering intricate imaging data, a feat that often surpasses human visual capabilities. They excel in detecting potential OMC lesions at an early stage, sometimes imperceptible to the human eye.⁸ The true potential of AI unfolds when we consider the remarkable applications of artificial neural networks (ANN) and convolutional neural networks (CNN) in the analysis of these imaging modalities.⁹ Artificial neural networks

(ANNs) simulate the brain's neural structure, recognizing intricate patterns within medical images and enhancing diagnosis efficiency, ultimately leading to better patient outcomes.¹⁰ Concurrently, convolutional neural networks (CNNs) have emerged as a revolutionary technology, specifically optimized for visual data analysis. They excel in extracting detailed features from imaging modalities, aiding in precise identification and differentiation of benign and malignant lesions, streamlining the diagnostic process, and enabling timely interventions. The integration of ANN and CNN technologies has significantly enhanced the accuracy and expediency of OMC diagnosis, crucial in healthcare where timely interventions impact prognosis and treatment outcomes.¹¹

For instance, Alabi *et al.*, 2022 discusses the technical knowledge and algorithms of deep learning for OSCC. It examines the application of deep learning technology in cancer detection, image classification, segmentation and synthesis, and treatment planning. The models have been integrated to offer an automated diagnosis of oral cancer. This approach offers the opportunity for cost-efficient early detection of oral cancer, which is the basis for the development of management of oral cancer.¹²

Distinguishing Benign and Malignant Lesions

Within the intricate landscape of Oral and Maxillofacial Cancer (OMC) diagnosis, the accurate differentiation between benign and malignant lesions stands as a pivotal challenge. This is precisely where the prowess of AI-driven image analysis becomes evident. Equipped with advanced capabilities in pattern recognition and data interpretation, these algorithms play a decisive role in navigating this critical distinction.¹³ By doing so, they ensure the formulation of precisely tailored treatment plans – a cornerstone of effective cancer management. The significance of this distinction cannot be overstated. Particularly in the field of OMC diagnosis, where the stakes are high, AI addresses the unique challenges and nuances associated with distinguishing between benign and malignant lesions. Misdiagnoses, especially those leading to unnecessary invasive procedures, not only inflict physical and emotional distress upon patients but also impose a substantial burden on healthcare resources. AI, with its keen

eye for subtle distinctions, effectively mitigates these risks. It not only raises the standard of patient care but also contributes to reducing healthcare costs and sparing individuals from unnecessary interventions

Predictive Models for OMC Risk Assessment

Machine learning algorithms, harmoniously integrated with AI, offer a comprehensive approach to evaluating an individual's risk of developing Oral and Maxillofacial Cancer (OMC). This entails processing diverse sets of data, including but not limited to medical history, genetic markers, lifestyle factors, and other pertinent information. The types of data considered in this risk assessment play a crucial role in refining the accuracy and specificity of predictive models.¹⁴ In the healthcare industry, particularly within the context of OMC risk assessment, various machine learning algorithms are employed. These algorithms harness the power of pattern recognition and data analysis to uncover intricate relationships within the collected data. While specific algorithms may vary, examples include decision trees, support vector machines, and neural networks, each contributing to the nuanced understanding of risk factors associated with OMC.¹⁵ For instance, a predictive model may intricately analyze a patient's medical history, considering lifestyle factors such as tobacco or alcohol use, and scrutinizing genetic markers. By leveraging this wealth of data, the model can effectively predict an individual's risk of developing OMC. The identification of high-risk individuals through such advanced algorithms not only allows for early interventions but also facilitates the implementation of targeted screening programs, ultimately enhancing the likelihood of early detection and improving overall outcomes.

Personalized Preventive Measures

AI emerges as a pivotal player in crafting personalized preventive measures for Oral and Maxillofacial Cancer (OMC). Leveraging machine learning algorithms, AI conducts thorough analyses of patients' lifestyle factors, genetic markers, and medical history, enabling the prediction of their individual risk of developing OMC. This predictive information becomes the cornerstone for tailoring preventive strategies that can significantly reduce the risk of OMC development. Consider a patient with a familial history of OMC and certain lifestyle factors, such as tobacco use.¹⁶ An AI model, drawing insights

from diverse data points, including age, gender, and overall health status, can predict the patient's specific risk of developing OMC. The personalized risk assessment guides the recommendation of targeted preventive measures. These measures may encompass regular screenings for early detection, lifestyle modifications such as tobacco and alcohol cessation, or even genetic counseling for those with identified high-risk genetic markers.¹⁷ Moreover, AI's role extends beyond the initial recommendation phase. It actively monitors the effectiveness of these preventive measures over time, analyzing changes in the patient's health data to assess the impact of the measures on reducing the risk of OMC. Should the data indicate a need for adjustments, AI facilitates adaptive modifications to the preventive strategies, ensuring ongoing optimization. This comprehensive approach underscores the importance of considering individual patient characteristics, ranging from genetic predispositions to lifestyle choices, in the formulation and adaptation of personalized preventive measures for OMC.

It is crucial to acknowledge that while the potential of AI in revolutionizing OMC diagnosis and management is significant, several challenges persist. These challenges encompass issues related to data privacy and security, the necessity for large and diverse datasets for robust AI model training, the interpretability of AI models, and the seamless integration of AI technologies into existing healthcare systems. Therefore, ongoing research and collaborative efforts among clinicians, researchers, and technologists remain paramount to fully realize the transformative benefits of AI in OMC diagnosis and management.

Oral and Maxillofacial Cancer (OMC) Staging and AI Applications

The staging of Oral and Maxillofacial Cancer (OMC) is a nuanced and critical process that profoundly influences treatment strategies and patient outcomes. Traditional staging methods involve a meticulous analysis of medical records, pathology reports, and imaging data. However, these methods are susceptible to human errors and variability.¹⁸ Enter Artificial Intelligence (AI), a transformative force poised to revolutionize the staging of OMC.

AI, mirroring human intelligence in machines, holds tremendous potential in elevating OMC staging. AI algorithms process extensive patient information, including intricate imaging data, with a precision that surpasses human capability. These algorithms excel in identifying crucial details such as tumor size, invasion depth, and lymph node involvement from imaging data, pivotal in determining the stage of the cancer. The seamless integration of AI into the staging process ensures consistency and accuracy, indispensable elements in crafting personalized treatment plans for OMC.¹⁹

Beyond conventional methodologies, AI facilitates dynamic estimation of patient survival rates, considering a myriad of individual patient factors and characteristics. Empowered with this foresight, clinicians can make well-informed decisions regarding treatment strategies and provide patients with a profound understanding of their prognosis.²⁰

However, as we embrace the transformative potential of AI in OMC staging, it is imperative to recognize and address the challenges that accompany responsible implementation. Ethical considerations, robust model validation, seamless integration into clinical practice, and data privacy concerns need meticulous attention. The responsible and ethical integration of AI into OMC staging demands collaboration and rigorous research.²¹

AI-driven applications in OMC staging signify a paradigm shift in the management of Oral and Maxillofacial Cancer. By automating and refining the staging process and providing predictive models for survival estimation, AI has the potential to significantly enhance patient outcomes and guide clinicians in making informed, personalized treatment decisions. However, it is essential to recognize and overcome the challenges that come with this transformation. Through relentless research and collaboration, we stand poised to unlock the full potential of AI in OMC staging and, consequently, in the broader landscape of oncology.

Oral and Maxillofacial Cancer (OMC) Treatment and AI Applications

Oral and Maxillofacial Cancer (OMC) poses a multifaceted challenge that demands a personalized approach to treatment. Fortunately, Artificial Intelligence (AI) has emerged as a transformative

force, unlocking immense potential in tailoring treatment plans, and optimizing radiation therapy for OMC patients.²² Let's delve into concrete examples and applications that vividly demonstrate AI's effectiveness in these critical domains.

Tailoring Treatment Plans with AI

AI's extraordinary strength lies in its ability to sift through vast quantities of patient data, transforming it into actionable insights and personalized treatment strategies. A prime illustration of this capability is IBM Watson for Oncology, an AI powerhouse that processes a vast array of medical literature, treatment protocols, and patient records. What sets it apart is its knack for delivering more than generic advice—it tailors recommendations according to the patient's unique attributes and medical history. This level of personalization enhances the precision and effectiveness of treatment plans.²³ Beyond personalized treatment recommendations, AI is propelling the domain of predictive analytics, especially in the realm of immunotherapies—an increasingly promising avenue in Oral and Maxillofacial Cancer (OMC) treatment. Immunotherapies like PD-1 inhibitors are gaining significant traction for their potential. AI algorithms, with their prowess in analyzing patient data, can predict the likelihood of a positive response to these therapies. This prediction becomes invaluable for clinicians, empowering them to make informed decisions regarding the most effective course of treatment for each patient.²⁴ AI can also play a significant role in optimizing chemotherapy for OMC patients.¹ Machine learning algorithms can analyze a patient's medical history, genetic markers, and response to previous treatments to predict the effectiveness of different chemotherapy drugs.¹ This could potentially improve treatment outcomes and reduce side effects.²⁵ In essence, AI is not just a computational marvel but a potent ally in the quest for more effective and personalized OMC treatments. Its influence extends to the forefront of immunotherapy, offering a glimpse of a future where treatments are tailored not only to the cancer type but also to the unique biological makeup and responses of individual patients.

AI in Radiation Therapy Planning

In radiation therapy, precision is the linchpin. AI is proving to be a game-changer in optimizing radiation therapy planning, enhancing accuracy while

minimizing collateral damage to healthy tissues.²⁶ A standout exemplar is RayStation, an AI-driven treatment planning system. RayStation employs machine learning to iteratively optimize treatment plans, saving crucial time for clinicians while ensuring an optimal radiation dose distribution.²⁷ Furthermore, Varian's Ethos™ adaptive intelligence technology stands as an impressive example of AI in radiation therapy optimization. Ethos™ continually monitors the treatment, adapting and modifying the treatment plan in real-time to ensure the best possible outcome.²⁸ This not only bolsters the efficacy of treatment but also markedly improves patient comfort and safety throughout the treatment process. These real-world examples vividly portray the practical impact of AI in tailoring treatment plans and optimizing radiation therapy for OMC patients. AI is no longer a futuristic vision, it's a present-day reality that's reshaping the landscape of cancer care.

AI-powered Robotic Surgery Systems

AI-powered robotic surgery systems have revolutionized the field of Oral and Maxillofacial Cancer (OMC) treatment. These systems, such as the pioneering da Vinci Surgical System, have transformed surgical procedures by enhancing precision and redefining surgical outcomes.²⁹ However, it's crucial to recognize that these systems come with their own set of challenges. One significant challenge is the steep learning curve for surgeons. Mastering the operation of these sophisticated AI-driven robotic systems requires dedicated training and experience. The initial phase of learning and adaptation can slow down the adoption of this technology in some healthcare settings. Another challenge is the cost of implementing and maintaining these systems. The initial investment in acquiring these systems, along with the ongoing operational expenses, can be substantial. This could potentially limit the widespread adoption of this technology, especially in healthcare environments with limited resources. Technical issues or errors during a surgical procedure present another area of concern. Despite their design to enhance surgical precision, AI-driven robotic systems are not immune to technical malfunctions or errors.³⁰ In case of a system glitch or error, the surgeon must be adept at swiftly switching to manual control or alternative approaches to ensure patient safety and the success of the surgical procedure. Despite these challenges, AI-powered

robotic surgery systems offer significant advantages. They enable minimally invasive procedures, which result in smaller incisions, reduced blood loss, and expedited recovery times for patients.³¹ This significantly enhances the overall postoperative experience. Moreover, these systems possess the unique capability to continuously learn and adapt from an extensive database of surgical data. This accumulated knowledge is then applied to subsequent surgeries, fine-tuning surgical techniques, and ultimately improving success rates. The incorporation of AI in Oral and Maxillofacial Cancer (OMC) treatment and prognosis holds the promise of transforming cancer care. It opens doors to personalized treatment plans, optimized therapeutic strategies, and enhanced patient outcomes. AI's predictive prowess empowers oncologists to make well-informed decisions, tailoring treatments to the unique needs and characteristics of individual OMC patients. When it comes to radiation therapy planning, AI steps in to enhance precision, ensuring treatment effectiveness while minimizing harm to healthy tissues. Additionally, AI-driven robotic surgery systems support surgeons in executing precise and minimally invasive procedures, ultimately leading to improved outcomes for patients during and after surgery. Embracing the advancements brought by AI can significantly elevate the success rates of OMC treatment and elevate the overall experience for patients, marking the onset of a new era in cancer care.

Empowerment of Oral and Maxillofacial Cancer (OMC) Education, Research, and Practice with ChatGPT

The intersection of healthcare and technology has led to significant advancements in the field of oral and maxillofacial cancer. Among these innovations, the integration of ChatGPT holds immense potential for revolutionizing cancer education, research, and practice, raising the standards of care in previously unimagined ways.

Personalized Patient Education

ChatGPT can play a pivotal role in educating patients about oral and maxillofacial cancer. Explaining complex medical jargon and treatment options can be challenging, often leaving patients bewildered. By incorporating ChatGPT, healthcare practitioners can provide personalized, easily comprehensible explanations. This not only empowers patients to

make informed decisions about their treatment journey but also fosters a sense of collaboration between patients and healthcare provider.³² Consider scenarios where ChatGPT tailors information based on individual patient characteristics and addresses specific concerns, enhancing the personalized education experience.

Accelerated Research Insights

Research is the cornerstone of medical advancement, particularly in the realm of cancer. ChatGPT can significantly expedite the research process by analyzing vast amounts of medical literature in a short span. It can identify patterns, highlight emerging trends, and propose novel research avenues. Researchers can leverage these insights to refine their studies and contribute to collective knowledge about oral and maxillofacial cancer.³³ Elaborate on how ChatGPT aids researchers in identifying specific patterns, trends, and suggesting potential research directions in the context of oral and maxillofacial cancer.

Enhanced Multidisciplinary Collaboration

Effective cancer treatment demands the collaboration of various specialists. ChatGPT can facilitate seamless communication among oncologists, surgeons, radiologists, and other experts involved in a patient's care. It can synthesize complex information, provide cross-specialty explanations, and offer real-time consultation suggestions. This ensures that the treatment approach is comprehensive and well-rounded.³⁴ Provide specific examples or scenarios where ChatGPT aids in cross-specialty communication, enhancing multidisciplinary collaboration.

Refined Treatment Planning

Developing a customized treatment plan is a complex task that relies on accurate information and careful consideration. ChatGPT can assist oncologists in comprehensively reviewing a patient's medical history, diagnostic reports, and treatment preferences. By offering additional insights based on its analysis, ChatGPT can contribute to fine-tuning treatment strategies for optimal outcomes.³⁵ Provide more details on how ChatGPT reviews patient information and contributes insights to the treatment planning process.

Empowerment in Palliative Care

For patients in advanced stages of oral and maxillofacial cancer, palliative care plays a critical role in improving their quality of life. ChatGPT can serve as a resource for suggesting pain management techniques, emotional support strategies, and even help patients articulate their feelings and concerns. This comprehensive approach can provide solace to both patients and their families.³² Consider providing specific examples of how ChatGPT assists in suggesting pain management techniques and providing emotional support in the context of oral and maxillofacial cancer.

The integration of ChatGPT into oral and maxillofacial cancer education, research, and practice marks a transformative juncture in the medical field. However, it's crucial to recognize that ChatGPT is a tool to enhance human capabilities rather than replace them. Remember, ChatGPT is a tool designed to assist and engage users in conversation, but it has its limitations and should be used responsibly.

Ethical Considerations of AI in Oral and Maxillofacial Cancer (OMC)

The integration of AI in Oral and Maxillofacial Cancer (OMC) care raises several ethical considerations, including patient privacy and data security. As AI algorithms rely on vast amounts of patient data, ensuring robust data protection measures and compliance with regulatory standards is paramount. Transparency and the ability to explain AI algorithms are essential to build trust between patients, clinicians, and AI systems.³⁶ For instance, consider a scenario where a ChatGPT-based system provides a detailed explanation of how it arrived at a certain treatment recommendation, reassuring both the patient and the healthcare provider about the reliability of the AI-driven insights.

Additionally, addressing potential biases in AI algorithms is crucial to ensure equitable healthcare delivery. In the context of OMC, biases in AI algorithms might manifest in various ways, such as disparities in the accuracy of diagnostic outcomes among different demographic groups. To mitigate these biases, it's essential to employ diverse and representative datasets during the development and training of AI models. For instance, a case study

could illustrate how a well-curated dataset from diverse patient populations helps reduce algorithmic biases and improves the reliability of OMC-related AI applications.³⁷

To overcome these challenges, continuous monitoring and evaluation of AI systems in OMC are necessary. Mechanisms for ongoing monitoring could include regular audits of AI algorithms, feedback loops that involve clinicians and patients, and dynamic updates to algorithms as new data becomes available or as the understanding of OMC evolves. This ensures that AI systems remain accurate, reliable, and aligned with the latest medical knowledge.³⁸

Interdisciplinary collaboration between clinicians, data scientists, and ethicists is crucial for addressing ethical considerations in AI applications in healthcare. Successful collaborations might involve joint efforts to establish ethical guidelines, develop frameworks for responsible AI use, and conduct regular reviews of AI systems. For example, highlighting a collaborative effort where clinicians provide valuable insights into the clinical context, data scientists contribute technical expertise, and ethicists ensure adherence to ethical principles can demonstrate the effectiveness of such interdisciplinary collaborations.³⁹

While AI brings transformative potential to OMC care, careful attention to ethical considerations is paramount. Continuous vigilance, transparency, and collaborative efforts will contribute to the responsible and ethical integration of AI in the management of Oral and Maxillofacial Cancer.

Future Directions of AI in Oral and Maxillofacial Cancer (OMC)

The future of AI in OMC holds promise for further advancements in precision medicine. One significant avenue is the integration of multi-omics data, encompassing genomics, proteomics, and metabolomics, with AI-driven algorithms. This integration aims to enhance patient risk stratification and treatment selection, offering a more comprehensive and accurate approach to personalized medicine. For example, AI algorithms can analyze intricate relationships within genomics data to identify specific genetic markers associated

with OMC risk, contributing to targeted and effective treatment strategies.⁴⁰

Furthermore, the integration of real-time patient monitoring data with AI systems is poised to revolutionize OMC treatment approaches. This integration facilitates dynamic treatment adjustments based on the evolving health status of the patient, allowing for timely interventions. For instance, AI algorithms can analyze continuous monitoring data to detect subtle changes in a patient's condition, prompting adjustments in treatment plans to optimize outcomes.⁴¹

Collaborative efforts among research institutions, healthcare providers, and technology developers are imperative for realizing the full potential of AI in OMC. Successful collaborations involve the sharing of expertise and resources to develop robust AI models tailored to the specific challenges of OMC.⁴²

Addressing the challenges and considerations in designing and conducting clinical trials for AI applications in OMC is crucial. Clinical trials and prospective studies play a pivotal role in validating the performance and impact of AI algorithms. Challenges may include defining appropriate endpoints, ensuring diverse and representative participant cohorts, and establishing standardized evaluation criteria. The design of such trials should align with ethical standards and regulatory guidelines to ensure the reliability and generalizability of the findings.⁴³

The future directions of AI in OMC are exciting and transformative. As we embark on this journey, the integration of multi-omics data, real-time patient monitoring, collaborative efforts, and rigorous clinical validation will be instrumental in unlocking the full potential of AI for precision medicine in Oral and Maxillofacial Cancer.

Conclusion

The potential of Artificial Intelligence (AI) to revolutionize the diagnosis, treatment, and prognosis of Oral and Maxillofacial Cancer (OMC) is undeniable. Throughout this manuscript, we have explored the transformative impact of AI-powered technologies, such as machine learning, deep learning, and computer vision, in enhancing OMC

risk assessment, accurate staging, and personalized treatment planning.

As we stand on the cusp of this technological evolution, it is imperative to acknowledge and address ethical concerns associated with the integration of AI in OMC care. Safeguarding patient privacy, ensuring transparency in AI algorithms, and mitigating algorithmic biases are paramount for the responsible deployment of AI in healthcare. By underscoring these ethical considerations and proposing solutions, we pave the way for a future where AI contributes meaningfully to OMC without compromising ethical standards.

Collaboration emerges as a central theme in unlocking the full potential of AI in routine clinical practice for OMC. The synergy of healthcare professionals, researchers, and policymakers is essential to navigate the complexities of AI implementation successfully. This collective effort fosters interdisciplinary collaboration, ensuring that AI advancements are seamlessly integrated into the fabric of OMC care.

In future, rigorous clinical trials and validation processes will be instrumental in establishing the reliability and efficacy of AI models in OMC, contributing to the building of trust among healthcare professionals and patients. This will further solidify the foundation for AI-driven transformations in OMC management.⁴⁴

In conclusion, the adoption of AI in OMC holds the promise of not only improving patient outcomes and enhancing clinical decision-making but also contributing significantly to the global effort to combat oral and maxillofacial cancer effectively. As we embrace these advancements, let us continue to work collaboratively, address ethical considerations, and propel further research, ultimately ensuring that AI becomes an invaluable tool in the comprehensive care of individuals affected by OMC.

Acknowledgement

The authors are profoundly grateful to Professor M. Shahabuddin Kabir Choudhuri, Chairman, Quest Bangladesh Biomedical Research Center, Dhaka, Bangladesh, for his continual support. The authors would also like to thank Professor Dr. Abu Syed Md. Mosaddek, Director, Clinical Affairs, Quest Bangladesh Biomedical Research Center, Dhaka, Bangladesh, for his supervision throughout this project.

Funding Sources

The author(s) received no financial support for the research authorship, and /or publication of this article.

Conflict of Interest

The author(s) do not have any conflict of interest.

References

1. Oral and oropharyngeal cancer—Statistics. Cancer.Net. Retrieved 10 October 2023, from <https://www.cancer.net/cancer-types/oral-and-oropharyngeal-cancer/statistics>.
2. González-Moles, M. Á., Aguilar-Ruiz, M., & Ramos-García, P. (2022). Challenges in the early diagnosis of oral cancer, evidence gaps and strategies for improvement: A scoping review of systematic reviews. *Cancers*, 14(19), 4967. <https://doi.org/10.3390/cancers14194967>
3. Jeihooni, A. K., & Jafari, F. (2021). Oral cancer: Epidemiology, prevention, early detection, and treatment. In *Oral Cancer—Current Concepts and Future Perspectives*. IntechOpen. <https://doi.org/10.5772/intechopen.99236>
4. Ilhan, B., Guneri, P., & Wilder-Smith, P. (2021). The contribution of artificial intelligence to reducing the diagnostic delay in oral cancer. *Oral Oncology*, 116, 105254. <https://doi.org/10.1016/j.oraloncology.2021.105254>
5. Ilhan, B., Lin, K., Guneri, P., & Wilder-Smith, P. (2020). Improving oral cancer outcomes with imaging and artificial intelligence. *Journal of Dental Research*, 99(3), 241–248. <https://doi.org/10.1177/0022034520902128>
6. Das, N. K., Kadir, A. K. M. S., Shemanto, M. U., Akhter, E., Sharfaraz, A., Tripura, S., Kundu, J., & Ura, A. A. (2023). Genetic revelation of the potentially malignant disorders in the oral

- and maxillofacial region. *IntechOpen*. <https://doi.org/10.5772/intechopen.112697>
7. Motie, P., Hemmati, G., Hazrati, P., Lazar, M., Varzaneh, F. A., Mohammad-Rahimi, H., Golkar, M., & Motamedian, S. R. (2023). Application of artificial intelligence in diagnosing oral and maxillofacial lesions, facial corrective surgeries, and maxillofacial reconstructive procedures. In A. Khojasteh, A. F. Ayoub, & N. Nadjmi (Eds.), *Emerging Technologies in Oral and Maxillofacial Surgery* (pp. 287–328). *Springer Nature*. https://doi.org/10.1007/978-981-19-8602-4_15
 8. Illimoottil, M., & Ginat, D. (2023). Recent advances in deep learning and medical imaging for head and neck cancer treatment: MRI, CT, and PET scans. *Cancers*, 15(13), 3267. <https://doi.org/10.3390/cancers15133267>
 9. Hellström, H., Liedes, J., Rainio, O., Malaspina, S., Kempainen, J., & Klén, R. (2023). Classification of head and neck cancer from PET images using convolutional neural networks. *Scientific Reports*, 13(1), 10528. <https://doi.org/10.1038/s41598-023-37603-1>
 10. Murugesan, G. K., Brunner, E., McCrumb, D., Kumar, J., VanOss, J., Moore, S., Peck, A., & Chang, A. (2022). Head and neck primary tumor segmentation using deep neural networks and adaptive ensembling. In V. Andrearczyk, V. Oreiller, M. Hatt, & A. Depoursing (Eds.), *Head and Neck Tumor Segmentation and Outcome Prediction* (pp. 224–235). *Springer International Publishing*. https://doi.org/10.1007/978-3-030-98253-9_21
 11. Barbhuiya, R. K., Ahmad, N., & Akram, W. (2022). Application of convolutional neural networks in cancer diagnosis. In K. Raza (Ed.), *Computational Intelligence in Oncology: Applications in Diagnosis, Prognosis and Therapeutics of Cancers* (pp. 95–109). *Springer*. https://doi.org/10.1007/978-981-16-9221-5_5
 12. Alabi, R. O., Almangush, A., Elmusrati, M., & Mäkitie, A. (2022, January 11). Deep Machine Learning for Oral Cancer: From Precise Diagnosis to Precision Medicine. *Frontiers in Oral Health*. <https://doi.org/10.3389/froh.2021.794248>
 13. Zhang, G., Zhu, L., Huang, R., Xu, Y., Lu, X., Chen, Y., Li, C., Lei, Y., Luo, X., Li, Z., Yi, S., He, J., & Zheng, C. (2023). A deep learning model for the differential diagnosis of benign and malignant salivary gland tumors based on ultrasound imaging and clinical data. *Quantitative Imaging in Medicine and Surgery*, 13(5), 2989–3000. <https://doi.org/10.21037/qims-22-950>
 14. Mogenet, A. (2022, May 9). Applying machine learning and AI to predict patient risk. Elsevier. Retrieved 10 October 2023, from <https://beta.elsevier.com/connect/applying-machine-learning-and-ai-to-predict-patient-risk?trial=true>
 15. Yang, C. C. (2022). Explainable artificial intelligence for predictive modeling in healthcare. *Journal of Healthcare Informatics Research*, 6(2), 228–239. <https://doi.org/10.1007/s41666-022-00114-1>
 16. Schork, N. J. (2019). Artificial intelligence and personalized medicine. In D. D. Von Hoff & H. Han (Eds.), *Precision Medicine in Cancer Therapy* (Vol. 178, pp. 265–283). *Springer International Publishing*. https://doi.org/10.1007/978-3-030-16391-4_11
 17. Sharma, K. Kr., Pawar, S. D., & Bali, B. (2020). Proactive preventive and evidence-based artificial intelligence models: Future healthcare. In G. Singh Tomar, N. S. Chaudhari, J. L. V. Barbosa, & M. K. Aghwariya (Eds.), *International Conference on Intelligent Computing and Smart Communication 2019* (pp. 463–472). *Springer*. https://doi.org/10.1007/978-981-15-0633-8_44
 18. Markiewicz, M. R., Callahan, N., & Morlandt, A. (2022). Oral cancer: Classification, diagnosis, and staging. In M. Miloro, G. E. Ghali, P. E. Larsen, & P. Waite (Eds.), *Peterson's Principles of Oral and Maxillofacial Surgery* (pp. 965–1008). *Springer International Publishing*. https://doi.org/10.1007/978-3-030-91920-7_33
 19. Farswan, A., Gupta, A., Gupta, R., Hazra, S., Khan, S., Kumar, L., & Sharma, A. (2021). AI-supported modified risk staging for multiple myeloma cancer useful in real-world scenario. *Translational Oncology*, 14(9), 101157.

- <https://doi.org/10.1016/j.tranon.2021.101157>
20. Bansal, K., Batla, R. K., Kumar, Y., & Shafi, J. (2022). Artificial intelligence techniques in health informatics for oral cancer detection. In S. Mishra, A. González-Briones, A. K. Bhoi, P. K. Mallick, & J. M. Corchado (Eds.), *Connected e-Health: Integrated IoT and Cloud Computing* (pp. 255–279). Springer International Publishing. https://doi.org/10.1007/978-3-030-97929-4_11
21. Kunstman, J. W. (2020). Artificial intelligence in cancer staging: Limitless potential or passing fad? *Annals of Surgical Oncology*, 27(4), 978–979. <https://doi.org/10.1245/s10434-019-08182-1>
22. Van Dijk, L. V., & Fuller, C. D. (2021). Artificial intelligence and radiomics in head and neck cancer care: Opportunities, mechanics, and challenges. *American Society of Clinical Oncology Educational Book*, 41, e225–e235. https://doi.org/10.1200/EDBK_320951
23. Zhou, N., Zhang, C.-T., Lv, H.-Y., Hao, C.-X., Li, T.-J., Zhu, J.-J., Zhu, H., Jiang, M., Liu, K.-W., Hou, H.-L., Liu, D., Li, A.-Q., Zhang, G.-Q., Tian, Z.-B., & Zhang, X.-C. (2019). Concordance study between ibmwatson for oncology and clinical practice for patients with cancer in china. *The Oncologist*, 24(6), 812–819. <https://doi.org/10.1634/theoncologist.2018-0255>
24. Ghaffari Laleh, N., Ligerio, M., Perez-Lopez, R., & Kather, J. N. (2023). Facts and hopes on the use of artificial intelligence for predictive immunotherapy biomarkers in cancer. *Clinical Cancer Research*, 29(2), 316–323. <https://doi.org/10.1158/1078-0432.CCR-22-0390>
25. Liang, G., Fan, W., Luo, H., & Zhu, X. (2020). The emerging roles of artificial intelligence in cancer drug development and precision therapy. *Biomedicine & Pharmacotherapy*, 128, 110255. <https://doi.org/10.1016/j.biopha.2020.110255>
26. Giordano, C., Brennan, M., Mohamed, B., Rashidi, P., Modave, F., & Tighe, P. (2021). Accessing artificial intelligence for clinical decision-making. *Frontiers in Digital Health*, 3. <https://www.frontiersin.org/articles/10.3389/fdgth.2021.645232>
27. Bodensteiner, D. (2018). RayStation: External beam treatment planning system. *Medical Dosimetry*, 43(2), 168–176. <https://doi.org/10.1016/j.meddos.2018.02.013>
28. Pokharel, S., Pacheco, A., & Tanner, S. (2022). Assessment of efficacy in automated plan generation for Varian Ethos intelligent optimization engine. *Journal of Applied Clinical Medical Physics*, 23(4), e13539. <https://doi.org/10.1002/acm2.13539>
29. Vijayakumar, M., & Shetty, R. (2020). Robotic surgery in oncology. *Indian Journal of Surgical Oncology*, 11(4), 549–551. <https://doi.org/10.1007/s13193-020-01251-y>
30. Goh, E. Z., & Ali, T. (2022). Robotic surgery: An evolution in practice. *Journal of Surgical Protocols and Research Methodologies*, 2022(1), snac003. <https://doi.org/10.1093/jsprm/snac003>
31. Kim, M., Zhang, Y., & Jin, S. (2023). Soft tissue surgical robot for minimally invasive surgery: A review. *Biomedical Engineering Letters*. <https://doi.org/10.1007/s13534-023-00326-3>
32. Sallam, M. (2023). Chatgpt utility in healthcare education, research, and practice: Systematic review on the promising perspectives and valid concerns. *Healthcare*, 11(6), 887. <https://doi.org/10.3390/healthcare11060887>
33. Hs Kumar, A. (2023). Analysis of chatgpt tool to assess the potential of its utility for academic writing in biomedical domain. *Biology, Engineering, Medicine and Science Reports*, 9(1), 24–30. <https://doi.org/10.5530/bems.9.1.5>
34. Cheng, K., Li, Z., Li, C., Xie, R., Guo, Q., He, Y., & Wu, H. (2023). The potential of gpt-4 as an ai-powered virtual assistant for surgeons specialized in joint arthroplasty. *Annals of Biomedical Engineering*, 51(7), 1366–1370. <https://doi.org/10.1007/s10439-023-03207-z>
35. Javaid, M., Haleem, A., & Singh, R. P. (2023). ChatGPT for healthcare services: An emerging stage for an innovative perspective. *BenchCouncil Transactions on Benchmarks, Standards and Evaluations*, 3(1), 100105. <https://doi.org/10.1016/j.tbench.2023.100105>
36. Hantel, A., Clancy, D. D., Kehl, K. L., Marron, J. M., Van Allen, E. M., & Abel, G. A. (2022). A process framework for ethically deploying artificial intelligence in oncology. *Journal of Clinical Oncology*, 40(34), 3907–3911. <https://doi.org/10.1200/JCO.2022.40.34.3907>

- doi.org/10.1200/JCO.22.01113
37. Locke T, Parker V, Thoumi A, Goldstein B, Silcox C (2022). Preventing Bias and Inequities in AI-enabled Health Tools. Washington, DC: Duke-Margolis Center for Health Policy
38. Reddy, S., Rogers, W., Makinen, V.-P., Coiera, E., Brown, P., Wenzel, M., Weicken, E., Ansari, S., Mathur, P., Casey, A., & Kelly, B. (2021). Evaluation framework to guide implementation of AI systems into healthcare settings. *BMJ Health & Care Informatics*, 28(1), e100444. <https://doi.org/10.1136/bmjhci-2021-100444>
39. Mittermaier, M., Raza, M., & Kvedar, J. C. (2023). Collaborative strategies for deploying AI-based physician decision support systems: Challenges and deployment approaches. *Npj Digital Medicine*, 6(1), 1–2. <https://doi.org/10.1038/s41746-023-00889-6>
40. Biswas, N., & Chakrabarti, S. (2020). Artificial intelligence (AI)-based systems biology approaches in multi-omics data analysis of cancer. *Frontiers in Oncology*, 10, 588221. <https://doi.org/10.3389/fonc.2020.588221>
41. AM, Jo Cavallo(2023). Patient-Facing Ai in Cancer Care - the Asco Post. <https://ascopost.com/news/november-2023/patient-facing-ai-in-cancer-care/>. Accessed 4 Dec. 2023.
42. PhD, Calley Jones. 'Emerging Applications of Artificial Intelligence in Cancer Care'. *American Association for Cancer Research (AACR)*, 1 Feb. 2022, <https://www.aacr.org/blog/2022/02/01/emerging-applications-of-artificial-intelligence-in-cancer-care/>.
43. Kather, Jakob Nikolas. 'Artificial Intelligence in Oncology: Chances and Pitfalls'. *Journal of Cancer Research and Clinical Oncology*, vol. 149, no. 10, Aug. 2023, pp. 7995–96. Springer Link, <https://doi.org/10.1007/s00432-023-04666-6>.
44. Khanagar, Sanjeev B., *et al.* 'Performance of Artificial Intelligence Models Designed for Diagnosis, Treatment Planning and Predicting Prognosis of Orthognathic Surgery (OGS)—A Scoping Review'. *Applied Sciences*, vol. 12, no. 11, May 2022, p. 5581. DOI.org (Crossref), <https://doi.org/10.3390/app12115581>.